scholarly journals Targeted therapeutic strategies for the management of renal cell carcinoma

2012 ◽  
Vol 24 (3) ◽  
pp. 284-290 ◽  
Author(s):  
Eric A. Singer ◽  
Gopal N. Gupta ◽  
Ramaprasad Srinivasan
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategies ◽  
Targeted Therapeutic

Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies

2012 ◽  
pp. 239-252
Author(s):  
Sumanta Kumar Pal ◽  
Karen Reckamp ◽  
Hua Yu ◽  
Robert A. Figlin ◽  
Robert A. Figlin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategies

scholarly journals How Can We Predict pT3a Kidney Cancer and What Does It Mean?

2021 ◽  
Vol 19 (4) ◽  
pp. 103-103
Author(s):  
Nirmish Singla
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Surgical Approach ◽  
Primary Tumor ◽  
Renal Cell ◽  
Retrospective Cohort ◽  
Therapeutic Strategies ◽  
Recurrence Free Survival ◽  
Radiological Findings ◽  
Free Survival

The ability to predict pathologically advanced renal cell carcinoma (RCC) within the primary tumor upfront can be helpful to guide prognostic counseling and hold implications for both surgical approach and multimodal therapeutic strategies. Herein, the investigators undertook a comprehensive assessment of radiographic features predictive of pT3a stage by querying 11 radiological findings across a robust retrospective cohort of patients with RCC. They found that an irregular tumor-sinus border (ITSB) correlated most strongly with pT3a stage and recurrence-free survival (RFS).

scholarly journals Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (16) ◽  
pp. 21259-21271 ◽  
Author(s):  
Lorena Incorvaia ◽  
Giuseppe Bronte ◽  
Viviana Bazan ◽  
Giuseppe Badalamenti ◽  
Sergio Rizzo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategies ◽  
Evidence Based ◽  
Scientific Rationale

Effect of targeted therapy on rapid progression and early death in renal cell carcinoma.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 389-389
Author(s):  
Shenhong Wu
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Cancer ◽  
Early Death ◽  
Therapeutic Agents ◽  
Rapid Progression ◽  
Significant Difference ◽  
Targeted Therapeutic

389 Background: Several targeted therapeutic agents have been approved for the treatment of advanced renal cell carcinoma (RCC) due to their efficacy in overall patient population. However, their effects have not been defined in patients with rapid progressive cancer, which is characterized by progression within three months and associated with poor prognosis. Therefore, we conducted a systematic review and meta-analysis of published randomized controlled clinical trials (RCTs) to assess the effect of targeted therapy on rapid progressive RCC. Methods: Databases from PUBMED, the Web of Science, and abstracts presented at the American Society of Clinical Oncology (ASCO) conferences until October, 2012, were searched to identify relevant studies. Rapid progression was defined as progressive disease or death at three months after the initiation of clinical trial. Eligible studies included prospective RCTs in which a targeted therapy was compared to a control in RCC patients. Summary incidence of rapid progression or death, relative risk (RR), and 95% confidence interval (CI) were calculated based on the heterogeneity of included studies. Results: A total of 4,628 patients (targeted therapy: 2,461, control: 2,167) with RCC from 10 RCTs were included for analysis. The overall incidence of cancer rapid progression with the targeted therapy was 23.6% (95% CI: 19.2-28.6%). When compared to controls including interferon or placebo, the targeted therapy significantly reduced the overall risk of rapid progression (23.6% vs. 54.5%; overall RR=0.46, 95% CI: 0.38-0.54, p<0.001; versus IFN: RR=0.55, versus placebo: RR=0.38). The effect varied significantly among different agents (p<0.001), with the highest reduction seen in patients treated with pazopanib (RR=0.27; 95% CI: 0.21-0.35). There was no significant difference between mTOR and VEGF inhibitors (p=0.25). In addition, the targeted therapy significantly reduced the risk of mortality at 3 months (5.5% vs. 10.0%; RR=0.58, 95% CI: 0.41-0.81; p=0.002). Conclusions: The targeted therapeutic agents may significantly reduce the risk of rapid progression and early death in patients with renal cell cancer.

scholarly journals A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy

2021 ◽  
Vol 11 ◽  
Author(s):  
Sung Han Kim ◽  
Min Gee Choi ◽  
Ji Hye Shin ◽  
Young-Ae Kim ◽  
Jinsoo Chung
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Disease Recurrence ◽  
Therapeutic Strategies ◽  
World Population ◽  
Significant Prognostic Factor ◽  
Primary Tumors ◽  
Localized Renal Cell Carcinoma

We retrospectively analyzed therapeutic strategies and risk factors for overall survival (OS) in disease recurrence following curative nephrectomy for localized renal cell carcinoma (loRCC) using the Korean National Cancer Registry Database. We selected 1295 recurrent loRCC patients who underwent either partial or radical nephrectomy from 2007–2013. Patients were excluded for age &lt;19 years, secondary RCC, multiple primary tumors, other SEER stages except for a localized or regional stage, postoperative recurrence within 3-month, and non-nephrectomized cases. Four therapeutic groups were statistically analyzed for OS and risk factors: surgery (OP, 12.0%), other systemic therapy (OST, 59.5%), radiotherapy (RT, 2.8%), and targeted therapy (TT, 25.8%). The overall mortality rate for recurrent loRCC was 32.5%, including 82.4% for RCC-related deaths. The baseline comparison among groups showed statistical differences for the diagnostic age of cancer and the SEER stage (p&lt;0.05). Multivariate analysis of OS showed significance for the TT (hazard ratio [HR]: 6.27), OST (HR: 7.05), and RT (HR: 7.47) groups compared with the OP group, along with significance for the sex, SEER stage, and the time from nephrectomy to treatment for disease recurrence (p&lt;0.05). The median OS curve showed a significantly better OS in the OP group (54.9 months) compared with the TT, OST, and RT groups (41.7, 42.9, and 38.0 months, respectively; p&lt;0.001). In conclusion, the surgery-treated group had the best OS among the different therapeutic strategies for recurrent loRCC after nephrectomy, and the importance of the time from nephrectomy to secondary treatment was a significant prognostic factor.

Sign in / Sign up

Export Citation Format

Share Document